A new tritium-release assay for 25-hydroxyvitamin D-1α-hydroxylase
✍ Scribed by Alex J. Brown; Kato Perlman; Heinrich K. Schnoes; Hector F. DeLuca
- Publisher
- Elsevier Science
- Year
- 1987
- Tongue
- English
- Weight
- 430 KB
- Volume
- 164
- Category
- Article
- ISSN
- 0003-2697
No coin nor oath required. For personal study only.
✦ Synopsis
A new, rapid assay for la-hydroxylase has been developed using 2%hydroxy-[ 1a-3H]vitamin D3 as the substrate. Using the solubilized and reconstituted chick la-hydroxylase, conversion of this substrate to 1,25-dihydroxyvitamin D3 causes the release of tritium into the aqueous medium. This 'Hz0 can be easily separated from the labeled substrate by passing the reaction mixture through a reverse-phase silica cartridge. The release of tritium is stereospecific as evidenced by the lack of 'Hz0 formed when 25-hydroxy-[l&'H]vitamin D3 is used as the substrate. In parallel reactions containing the 25-hydroxy-[26,27-'H]vitamin D3 substrate, production of labeled 1,25dihydroxyvitamin D3 was assessed by extraction and high-performance liquid chromatography and found to agree very closely with the amount of 'Hz0 produced from 25-hydroxy-[ la-'HIvitamin D3, validating the accuracy of the new assay. Finally, a major advantage of the tritium-release assay for I ol-hydroxylase is that the results are not affected by further metabolism of the 1,25-dihydroxyvitamin D formed in the incubations. a 1987 Academic Pres.s, Inc.
📜 SIMILAR VOLUMES
## Abstract We examined parathyroid and skeletal function in 3‐month‐old mice expressing the null mutation for 25‐hydroxyvitamin D–1α‐hydroxylase [__1α(OH)ase__^−/−^] and in mice expressing the null mutation for both the __1α(OH)ase__ and the calcium‐sensing receptor [__Casr__^__−/−__^__1α(OH)ase__
The effects of 1␣-hydroxyvitamin D 3 [1␣(OH)D 3 ] and 1,25dihydroxyvitamin D 3 [1,25(OH) 2 D 3 ] on the incidence of colon tumors induced by azoxymethane and on the labeling index and angiogenesis of colon tumors were investigated in Wistar rats. Rats received 10 weekly injections of 7.4 mg/kg body